Press Releases Year: - Any -202020192018201720162015201420132012201120102009 Items per page 102550 Date Title and Summary Additional Formats Toggle Summary May 20, 2013 Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer View HTML Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 17.7 KB Toggle Summary Apr 18, 2013 Data Presented at OARSI’s 2013 World Congress on Osteoarthritis Show Flexion’s FX006 Has Prolonged Therapeutic Concentration in Knee Joint View HTML Data Presented at OARSI’s 2013 World Congress on Osteoarthritis Show Flexion’s FX006 Has Prolonged Therapeutic Concentration in Knee Joint 19.4 KB Toggle Summary Jan 04, 2013 Flexion Therapeutics to Present at 31st Annual J.P. Morgan Healthcare Conference View HTML Toggle Summary Dec 17, 2012 Flexion's FX006 Achieves Prolonged Therapeutic Concentrations in Joints of Osteoarthritis Patients View HTML Toggle Summary Dec 04, 2012 Flexion Therapeutics Secures $20 Million in Series B Financing View HTML Toggle Summary Jun 19, 2012 Flexion Therapeutics Names Arthur Fratamico Chief Business Officer View HTML Toggle Summary Jan 29, 2010 Flexion Therapeutics Announces Agreements with Four Major Pharmaceutical Companies View HTML Toggle Summary Oct 16, 2009 Flexion Therapeutics Raises $33 Million in Series A Financing View HTML Pagination First page First Previous page Previous … Page 22 Page 23 Page 24 Current page 25
Press Releases Year: - Any -202020192018201720162015201420132012201120102009 Items per page 102550 Date Title and Summary Additional Formats Toggle Summary May 20, 2013 Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer View HTML Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 17.7 KB Toggle Summary Apr 18, 2013 Data Presented at OARSI’s 2013 World Congress on Osteoarthritis Show Flexion’s FX006 Has Prolonged Therapeutic Concentration in Knee Joint View HTML Data Presented at OARSI’s 2013 World Congress on Osteoarthritis Show Flexion’s FX006 Has Prolonged Therapeutic Concentration in Knee Joint 19.4 KB Toggle Summary Jan 04, 2013 Flexion Therapeutics to Present at 31st Annual J.P. Morgan Healthcare Conference View HTML Toggle Summary Dec 17, 2012 Flexion's FX006 Achieves Prolonged Therapeutic Concentrations in Joints of Osteoarthritis Patients View HTML Toggle Summary Dec 04, 2012 Flexion Therapeutics Secures $20 Million in Series B Financing View HTML Toggle Summary Jun 19, 2012 Flexion Therapeutics Names Arthur Fratamico Chief Business Officer View HTML Toggle Summary Jan 29, 2010 Flexion Therapeutics Announces Agreements with Four Major Pharmaceutical Companies View HTML Toggle Summary Oct 16, 2009 Flexion Therapeutics Raises $33 Million in Series A Financing View HTML Pagination First page First Previous page Previous … Page 22 Page 23 Page 24 Current page 25
Data Presented at OARSI’s 2013 World Congress on Osteoarthritis Show Flexion’s FX006 Has Prolonged Therapeutic Concentration in Knee Joint 19.4 KB
